EYEPOINT PHARMACEUTICALS
EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.
EYEPOINT PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1987-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.eyepointpharma.com
Total Employee:
101+
Status:
Active
Contact:
617-926-5050
Email Addresses:
[email protected]
Total Funding:
437.9 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Maps Microsoft Azure DNS COVID-19 Microsoft Network Solutions DNS Mimecast
Similar Organizations
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
AcelRx Pharmaceuticals
AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of pain and other conditions.
Adnoviv
Adnoviv specializes in the development and commercialization of intelligent sensors and systems for industrial and security applications.
Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company developing products for the treatment of glaucoma.
Annidis Health Systems
Annidis Health Systems engages in the research, development and commercialization of medical devices for eye-care professionals.
Antares Pharma
Antares Pharma is a specialty pharmaceutical company that focuses on commercializing therapeutic products.
Apollo Pharmaceuticals USA
Apollo Pharmaceuticals USA is specialized in the commercialization of sterile injectable products for hospital use.
Breg
Breg, Inc. manufactures and markets sports medicine products and services for orthopedic patient care.
Charles River Laboratories International
Charles River Laboratories International provides research models and outsourced preclinical services for the accelerated R&D of drugs.
CM&D Pharma Ltd
CM&D Pharma Limited engages in the development and commercialization of products for dietary management.
Cmed
Cmed is a full service, global CRO specialized in the design and delivery of innovative and traditional early phase patient clinical trials.
Connetics
Connetics Corporation engages in the development and commercialization of products for the medical dermatology market.
Consort Medical
Consort Medical offers medical device technologies for drug delivery and hospital products for the management of patient airways.
Densmore Pharmaceutical Laboratory
Densmore, a natural food supplement laboratory mainly specialising in ophthalmic solutions to treat eye diseases.
Eli Lilly
Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
First Choice Health
First Choice Health specializes in health plan administration, employee assistance programs and medical management services.
GT Biopharma
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Interventional Spine
Interventional Spine develops and commercializes patented percutaneous systems for the treatment of back pain.
JA Saúde Animal
J.A Saúde Animal specializes in research, development, manufacturing, and commercialization of products for animal health.
Lucane Pharma
Lucane Pharma is specialised in the development and commercialisation of medicinal products targeting rare disorders
Midwest Eye Consultants
Midwest Eye Consultants provides total eye care from eye health exams to the treatment of eye diseases.
Pharmaceutical Biotechnology
Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.
Pharmion
Pharmion engages in the acquisition, development, and commercialization of products for the treatment of hematology and oncology patients.
Qilu Tianhe Pharmaceutical
Qilu Tianhe Pharmaceutical specializes in developing and manufacturing of generic drugs and active pharmaceutical ingredients.
Rejuvenon
Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Sanare Bioscience
Sanare Bioscience specializes in the development and commercialization of medical products that improve patient outcomes.
Santhera Pharmaceuticals
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Sprout Pharmaceuticals
Sprout Pharmaceuticals is a medical company that develops products for the treatment of female sexual dysfunction.
Tianjin Pharmaceutical
Tianjin Pharmaceutical specializes in the development of oral liquid products and sales services.
Tripos International
Tripos Discovery Informatics engages in the identification and optimization of new compounds that have the potential to become drug
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
USUN BIO
USUN BIO specializes in the development and application of non-steroidal anti-inflammatory drugs.
Valcrest Pharmaceuticals
Valcrest Pharmaceuticals specializes in the development and commercialization of novel pharmaceutical products.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
ViroPharma
ViroPharma, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-03-28 | Icon Bioscience | Icon Bioscience acquired by EyePoint Pharmaceuticals | N/A |
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - EyePoint Pharmaceuticals
Ocumension Therapeutics
Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals
CRG
CRG investment in Debt Financing - EyePoint Pharmaceuticals
EW Healthcare Partners
EW Healthcare Partners investment in Post-IPO Equity - EyePoint Pharmaceuticals
Rosalind Advisors
Rosalind Advisors investment in Post-IPO Equity - EyePoint Pharmaceuticals
RA Capital Management
RA Capital Management investment in Post-IPO Equity - EyePoint Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.eyepointpharma.com Semrush global rank: 3.52 M Semrush visits lastest month: 4.21 K
- Host name: 47.78.215.35.bc.googleusercontent.com
- IP address: 35.215.78.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "EyePoint Pharmaceuticals" on Search Engine
Management | EyePoint Pharmaceuticals
Jay S. Duker, MD, is the President & CEO and Board Director of EyePoint Pharmaceuticals, a biopharmaceutical company that develops sustained-release …See details»
EyePoint Pharmaceuticals Announces Chief Executive Officer …
WATERTOWN, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing …See details»
EyePoint Pharmaceuticals Reports Fourth Quarter and
Mar 3, 2022 EyePoint Pharmaceuticals will retain the DEXYCU NDA, revenue recognition, manufacturing, and distribution responsibilities for all markets. The amended …See details»
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial …
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing …See details»
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and …
Dec 31, 2021 WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to …See details»
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and …
WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and …See details»
EyePoint Pharmaceuticals Reports Inducement Grants Under …
3 days ago WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and …See details»
EyePoint Pharmaceuticals - Company Profile - GlobalData
Apr 17, 2023 EyePoint Pharmaceuticals - Company Profile. Powered by. All the data and insights you need on EyePoint Pharmaceuticals in one report. $295. Buy Report View …See details»
Scott Jones, M.A. - EyePoint Pharmaceuticals
Chief Commercial Officer. As Chief Commercial Officer of EyePoint Pharmaceuticals, Scott Jones draws on his significant experience commercializing drugs and devices globally to …See details»
EyePoint Pharmaceuticals - Crunchbase Company Profile
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases. Watertown, Massachusetts, …See details»
EyePoint Pharmaceuticals Reports Inducement Grants Under …
5 days ago WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and …See details»
Maintained Buy Rating on EyePoint Pharmaceuticals Amid …
4 days ago EyePoint Pharmaceuticals (EYPT) Company Description: EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development …See details»
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue …
May 10, 2024 For Q1 2024, EyePoint Pharmaceuticals reported a revenue of $11.7 million, which is a substantial increase from $7.7 million in the same quarter the previous …See details»
EyePoint Pharmaceuticals’s cGMP Manufacturing Facility, USA
Mar 12, 2024 January 2024. Expected Completion. Second half of 2024. EyePoint Pharmaceuticals’s cGMP manufacturing facility will be built in Northbridge, …See details»
EyePoint Pharmaceuticals Reports Inducement Grants Under
3 days ago The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint …See details»
Michael Pine | Management | EyePoint Pharmaceuticals
Michael Pine. Chief Business Officer. As Chief Business Officer, Michael Pine draws on his more than 20 years of industry experience in business development & licensing, …See details»
George O. Elston - EyePoint Pharmaceuticals
O Elston leads EyePoint Pharmaceuticals’ financial, capital markets, and corporate development initiatives. Mr. Elston has leveraged his more than 30 years of diverse …See details»
EyePoint Pharmaceuticals - Funding, Financials, Valuation
Funding. EyePoint Pharmaceuticals has raised a total of. $653.8M. in funding over 10 rounds. Their latest funding was raised on Dec 5, 2023 from a Post-IPO Equity round. …See details»
Insider Sale: Director David Guyer Sells Shares of EyePoint ...
3 days ago On the date of the transaction, shares of EyePoint Pharmaceuticals Inc were priced at $12.65. This pricing gives the company a market cap of approximately …See details»
Eyepoint Pharmaceuticals director sells over $147k in stock
4 days ago EYPT. -3.32%. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) director David R. Guyer has recently engaged in significant trading activity, according to the …See details»